4D Molecular Therapeutics, Inc.
FDMT
$26.38
$0.000.00%
| Weiss Ratings | FDMT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | FDMT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | FDMT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.86 | |||
| Price History | FDMT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -2.06% | |||
| 30-Day Total Return | -15.63% | |||
| 60-Day Total Return | 43.65% | |||
| 90-Day Total Return | 39.53% | |||
| Year to Date Total Return | 16.61% | |||
| 1-Year Total Return | 20.47% | |||
| 2-Year Total Return | 108.76% | |||
| 3-Year Total Return | -32.70% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -35.09% | |||
| 52-Week Low % Change | 149.26% | |||
| Price | FDMT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $36.25 | |||
| 52-Week Low Price | $9.44 | |||
| 52-Week Low Price (Date) | Oct 17, 2023 | |||
| 52-Week High Price (Date) | Mar 27, 2024 | |||
| Valuation | FDMT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.29B | |||
| Enterprise Value | 1.01B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -2.64 | |||
| Earnings Per Share Growth | -20.41% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 52.24 | |||
| Price/Book (Q) | 3.53 | |||
| Enterprise Value/Revenue (TTM) | 44.36 | |||
| Price | $24.78 | |||
| Enterprise Value/EBITDA (TTM) | -8.46 | |||
| Enterprise Value/EBIT | -8.14 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | FDMT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 42.87M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | FDMT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 510 505 2680 | |||
| Address | 5858 Horton Street Emeryville, CA 94608 | |||
| Website | www.4dmoleculartherapeutics.com | |||
| Country | United States | |||
| Year Founded | 2013 | |||
| Profitability | FDMT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -544.67% | |||
| Profit Margin | -486.61% | |||
| Management Effectiveness | FDMT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -23.45% | |||
| Return on Equity | -- | |||
| Income Statement | FDMT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 20.72M | |||
| Total Revenue (TTM) | 20.72M | |||
| Revenue Per Share | $0.48 | |||
| Gross Profit (TTM) | 10.99M | |||
| EBITDA (TTM) | -108.66M | |||
| EBIT (TTM) | -112.87M | |||
| Net Income (TTM) | -100.84M | |||
| Net Income Avl. to Common (TTM) | -100.84M | |||
| Total Revenue Growth (Q YOY) | -101.52% | |||
| Earnings Growth (Q YOY) | -17.91% | |||
| EPS Diluted (TTM) | -2.64 | |||
| EPS Diluted Growth (Q YOY) | 10.63% | |||
| Balance Sheet | FDMT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 288.23M | |||
| Cash Per Share (Q) | $6.72 | |||
| Total Current Assets (Q) | 296.59M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 307.83M | |||
| Current Ratio (Q) | 15.650 | |||
| Book Value Per Share (Q) | $7.15 | |||
| Total Assets (Q) | 339.89M | |||
| Total Current Liabilities (Q) | 18.95M | |||
| Total Debt (Q) | 14.67M | |||
| Total Liabilities (Q) | 32.06M | |||
| Total Common Equity (Q) | 307.83M | |||
| Cash Flow | FDMT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 115.72M | |||
| Cash from Financing (TTM) | 156.83M | |||
| Net Change in Cash (TTM) | 196.76M | |||
| Levered Free Cash Flow (TTM) | -46.53M | |||
| Cash from Operations (TTM) | -75.79M | |||
